I 
119TH CONGRESS 
1ST SESSION H. R. 1432 
To prohibit any Federal law from making the manufacturer of a COVID– 
19 vaccine immune from suit or liability, or limiting the liability of 
such a manufacturer, with respect to claims for loss caused by, arising 
out of, relating to, or resulting from the administration to or the use 
by an individual of a COVID–19 vaccine, and for other purposes. 
IN THE HOUSE OF REPRESENTATIVES 
FEBRUARY 18, 2025 
Mr. ROY (for himself, Mr. MASSIE, Mr. BRECHEEN, Mr. CLOUD, Mr. HIGGINS 
of Louisiana, Mr. CRANE, Mr. GOSAR, and Mr. PERRY) introduced the 
following bill; which was referred to the Committee on the Judiciary 
A BILL 
To prohibit any Federal law from making the manufacturer 
of a COVID–19 vaccine immune from suit or liability, 
or limiting the liability of such a manufacturer, with 
respect to claims for loss caused by, arising out of, 
relating to, or resulting from the administration to or 
the use by an individual of a COVID–19 vaccine, and 
for other purposes. 
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled, 
VerDate Sep 11 2014 
01:13 Mar 12, 2025
Jkt 059200
PO 00000
Frm 00001
Fmt 6652
Sfmt 6201
E:\BILLS\H1432.IH
H1432
ssavage on LAPJG3WLY3PROD with BILLS
SECTION 1. SHORT TITLE. 
This Act may be cited as the ‘‘Let Injured Americans 
Be Legally Empowered Act’’ or the ‘‘LIABLE Act’’. 
SEC. 2. NO FEDERAL IMMUNITY FROM, OR LIMITATION ON, 
LIABILITY FOR MANUFACTURERS FOR LOSS 
CAUSED BY A COVID–19 VACCINE. 
(a) IN GENERAL.—No Federal law, including sec-
tions 319F–3, 2111, and 2122 of the Public Health Serv-
ice Act (42 U.S.C. 247d–6d, 300aa–11, 300aa–22), may 
make the manufacturer of a COVID–19 vaccine immune 
from suit or liability, or limit the liability of such a manu-
facturer, with respect to claims for loss caused by, arising 
out of, relating to, or resulting from the administration 
to or the use by an individual of a COVID–19 vaccine. 
(b) RULE OF CONSTRUCTION.—Nothing in this Act 
shall be construed to prohibit an individual from seeking 
compensation through the Countermeasures Injury Com-
pensation Program under section 319F–4 of the Public 
Health Service Act (42 U.S.C. 247d–6e) or the National 
Vaccine Injury Compensation Program under subtitle 2 
of title XXI of such Act (42 U.S.C. 300aa–10 et seq.). 
(c) RELATION TO OTHER PROGRAMS.—An individual 
shall not be precluded from bringing a civil action for 
claims described in subsection (a) on the basis of such in-
dividual having sought or received compensation through 
the Countermeasures Injury Compensation Program 
VerDate Sep 11 2014 
01:13 Mar 12, 2025
Jkt 059200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6201
E:\BILLS\H1432.IH
H1432
ssavage on LAPJG3WLY3PROD with BILLS
under section 319F–4 of the Public Health Service Act 
(42 U.S.C. 247d–6e) or the National Vaccine Injury Com-
pensation Program under subtitle 2 of title XXI of such 
Act (42 U.S.C. 300aa–10 et seq.). 
(d) DEFINITION.—The term ‘‘COVID–19 vaccine’’ 
means a vaccine licensed or otherwise authorized by the 
Food and Drug Administration to prevent, mitigate, or 
limit— 
(1) the harm from COVID–19; or 
(2) the transmission of SARS–CoV–2 or a virus 
mutating therefrom. 
(e) RETROACTIVE APPLICABILITY.—This Act applies 
without regard to whether the adminstration or use of a 
COVID–19 vaccine occurs before, on, or after the date of 
enactment of this Act. 
Æ 
VerDate Sep 11 2014 
01:13 Mar 12, 2025
Jkt 059200
PO 00000
Frm 00003
Fmt 6652
Sfmt 6301
E:\BILLS\H1432.IH
H1432
ssavage on LAPJG3WLY3PROD with BILLS